Jonathan Silverstein Net Worth

The estimated Net Worth of Jonathan Silverstein is at least $319 Million dollars as of 2 October 2020. Mr. Silverstein owns over 496,000 units of Arcutis Biotherapeutics Inc stock worth over $9,492,049 and over the last 17 years he sold ARQT stock worth over $309,727,397. In addition, he makes $0 as Independent Director at Arcutis Biotherapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Silverstein ARQT stock SEC Form 4 insiders trading

Jonathan has made over 20 trades of the Arcutis Biotherapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 496,000 units of ARQT stock worth $12,400,000 on 2 October 2020.

The largest trade he's ever made was selling 836,500 units of Arcutis Biotherapeutics Inc stock on 2 March 2018 worth over $26,784,730. On average, Jonathan trades about 137,684 units every 69 days since 2007. As of 2 October 2020 he still owns at least 902,286 units of Arcutis Biotherapeutics Inc stock.

You can see the complete history of Mr. Silverstein stock trades at the bottom of the page.

Jonathan Silverstein biography

Jonathan T. Silverstein J.D. serves as Independent Director of the Company. Mr. Silverstein is currently a Managing Partner and a Co-Head of Global Private Equity at OrbiMed Advisors, a healthcare investment firm, where he has worked since December 1998. Previously, Mr. Silverstein was a director of life sciences in the investment banking department at Sumitomo Bank. Mr. Silverstein currently serves on the board of directors of resTORbio, Inc. and Avedro Inc. Mr. Silverstein has also previously served on the board of directors of Audentes Therapeutics, Inc., Ascendis Pharma A/S, Intercept Pharmaceuticals, Inc., Glaukos Corporation, scPharmaceuticals Inc., Rhythm Pharmaceuticals, Inc. and Sorrento Tech, Inc. (formerly known as Roka BioScience, Inc.). Mr. Silverstein received a B.A. from Denison University and a J.D. and M.B.A. from the University of San Diego.

How old is Jonathan Silverstein?

Jonathan Silverstein is 53, he's been the Independent Director of Arcutis Biotherapeutics Inc since 2018. There are 11 older and 15 younger executives at Arcutis Biotherapeutics Inc. The oldest executive at Arcutis Biotherapeutics Inc is Howard Welgus, 68, who is the Director.

What's Jonathan Silverstein's mailing address?

Jonathan's mailing address filed with the SEC is C/O ARCUTIS BIOTHERAPEUTICS, INC., SUITE 110, WESTLAKE VILLAGE, CA, 91361.

Insiders trading at Arcutis Biotherapeutics Inc

Over the last 5 years, insiders at Arcutis Biotherapeutics Inc have traded over $33,184,604 worth of Arcutis Biotherapeutics Inc stock and bought 3,754,945 units worth $71,202,175 . The most active insiders traders include Jonathan Silverstein, Patrick J Heron und Advisors Llcorbimed Capital.... On average, Arcutis Biotherapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $361,425. The most recent stock trade was executed by Howard G. Welgus on 3 September 2024, trading 10,000 units of ARQT stock currently worth $107,700.

What does Arcutis Biotherapeutics Inc do?

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.

Complete history of Mr. Silverstein stock trades at Insulet, Intercept Pharmaceuticals Inc, Glaukos, Rhythm Pharmaceuticals, scPharmaceuticals Inc, resTORbio und Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc executives and stock owners

Arcutis Biotherapeutics Inc executives and other stock owners filed with the SEC include:

• Todd Watanabe,
  President, Chief Executive Officer, Director
• Kenneth Lock,
  Chief Commercial Officer
• Todd Franklin Watanabe M.A.,
  Pres, CEO & Director
• Patricia Turney,
  Senior Vice President - Manufacturing
• Dr. Patrick E. Burnett M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Kenneth A. Lock,
  Chief Commercial Officer
• Bhaskar Chaudhuri,
  Independent Director
• Joseph Turner,
  Independent Director
• Ricky Sun,
  Independent Director
• Jonathan Silverstein,
  Independent Director
• Howard Welgus,
  Director
• Halley Gilbert,
  Director
• Terrie Curran,
  Director
• Patrick Burnett,
  Chief Medical Officer
• Keith Klein,
  General Counsel
• Frank Pompilio,
  Vice President - Medical Affairs
• Lynn Navale,
  Vice President - Biometrics
• Charlotte Merritt,
  Vice President - Regulatory Affairs
• Ayisha Jeter,
  Vice President of Market Access
• Meg Elias,
  Vice President - Clinical Operations
• Bethany Dudek,
  Vice President - Quality
• David Berk,
  Vice President - Clinical Development
• Heather Armstrong,
  Vice President of Investor Relations and Corporate Communications
• Kimberly Lathroum,
  Vice President of Marketing
• Jay Ramsinghani,
  Vice President of Commercial Strategy and Operations
• Scott Burrows,
  Vice President - Finance
• John Smither,
  Chief Financial Officer
• David Osborne,
  Co-Founder, Chief Technical Officer
• Patrick Heron,
  Independent Chairman of the Board
• Masaru Matsuda Esq., J.D.,
  Gen. Counsel & Corp. Sec.
• Courtney Barton,
  Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer
• Eric McIntyre,
  Head of Investor Relations
• Dr. David W. Osborne,
  Chief Technical Officer
• Patricia A. Turney,
  Sr. VP of Operations
• Scott L. Burrows,
  CFO & Principal Accounting Officer
• Larry Todd Edwards,
  SVP Chief Commercial Officer
• Daniel Estes,
  Director
• Neha Krishnamohan,
  Director
• David Joseph Topper,
  Chief Financial Officer
• Masaru Matsuda,
  See Remarks
• Capital Life Sciences Inves...,
  
• Advisors Llcorbimed Capital...,
  
• Life Sciences Viii, L.P.Fhm...,
  
• Matthew Richard Moore,
  SVP and Chief Business Officer
• Life Sciences Viii, L.P.Fhm...,
  
• Sue Jean Lin,
  Director
• Keith R Leonard,
  Director
• Life Sciences Viii, L.P.Fhm...,